Hagens Berman Launches Investigation into Madrigal Pharmaceuticals Over Clinical Data Integrity Concerns

Hagens Berman Investigates Madrigal Pharmaceuticals



In a significant development, the national law firm Hagens Berman has initiated an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The primary focus of this inquiry centers around allegations of possible wrongdoing related to the integrity of clinical data for Rezdiffra (resmetirom), a medication developed by the company. The investigation has been prompted by whistleblower claims that suggest serious deficiencies in both clinical practices and internal controls.

Background of the Investigation



The investigation was announced after Madrigal's former Senior Vice President and Head of Clinical Development, Dr. Michael Charlton, filed a whistleblower complaint. This complaint highlights numerous alleged deficiencies concerning the safety data related to Rezdiffra. Specifically, it asserts that senior management may have misrepresented or concealed critical adverse facts that could affect both investor confidence and regulatory compliance.

Among the key allegations outlined in the complaint are:
  • - Suppression of Adverse Safety Events: It is claimed that senior executives ignored red flags about suppressed data regarding liver injuries in clinical trials.
  • - Discrepancies in Efficacy Data: There are assertions that the efficacy results reported could not be substantiated by original source data, raising questions about the drug’s effectiveness.
  • - Improper Board Oversight: The complaint suggests that a non-blinded member of the Board of Directors improperly influenced the adjudication of clinical outcomes, undermining the integrity of the trial results.

Following the announcement of these serious allegations, Madrigal's stock experienced a significant decline, dropping over 8%, equating to a loss of $34.84 per share.

Investor Impact



Hagens Berman is reaching out to investors who may have suffered financial losses due to the alleged misconduct at Madrigal. The firm encourages individuals to submit their trading information to assist in the investigation. According to Reed Kathrein, the partner leading this investigation, the focus is on establishing a timeline regarding when Madrigal executives became aware of the alleged clinical trial irregularities and whether investors were misled regarding the safety and reliability of Rezdiffra’s clinical data.

Investors who believe they have relevant information, or who have incurred substantial losses, are urged to submit their details to the firm. Furthermore, whistleblowers with insider information are encouraged to utilize the SEC Whistleblower program. This program offers rewards up to 30% for those providing original information that leads to successful recovery efforts by the SEC.

About Hagens Berman



Hagens Berman Sobol Shapiro LLP is recognized as a global leader in plaintiff rights and complex litigation. The firm specializes in ensuring corporate accountability and represents a diverse range of clients, including investors and whistleblowers. Their commitment to securing justice for those affected by corporate negligence is undeniable, having successfully recovered over $2.9 billion for clients in the past.

In conclusion, the ongoing investigation into Madrigal Pharmaceuticals underscores the importance of transparency and integrity within clinical trials. As more information unfolds, stakeholders will be closely monitoring developments in this case, particularly the potential ramifications for both the company and its investors.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.